An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours

NCT04440956 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: 64Cu-SARTATE

Sponsor

Clarity Pharmaceuticals Ltd